J&J CEO Gorsky Handing Over The Reins To Vice Chairman Duato
Gorsky Will Transition To Executive Chairman
Executive Summary
Duato has been involved for the last several years in growing J&J’s pharma and consumer businesses and has led the company’s COVID-19 efforts. Gorsky is stepping down due to a family health issue.
You may also be interested in...
Q4 Earnings Preview: Setting The Tone For 2022 (Part 1)
Biopharma will outline its growth goals for 2022 over the coming weeks, with J&J, Novartis, AbbVie, Merck, Roche, Biogen and Lilly among the first to report.
CEO Pay Packages Expand in India But Ratio To Employee Earnings Hurts
Top executives at leading local and foreign drug firms in India by and large earned more in 2020-21, while differentials in CEO to median employee remuneration remained stark. With increasing scrutiny by shareholders and lawmakers, experts suggest that pharma should be more mindful of balancing “adequate” C-suite compensation and glaring inequalities.
J&J Expects A Commercial COVID-19 Vaccine Market By Late 2022/2023
The company is currently providing its COVID-19 vaccine on a not-for-profit basis but expects that will change as the pandemic phase of the crisis abates.